Withdrawal Syndrome Clinical Trial
— NEUROSEVOfficial title:
Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses: Randomized Controlled Trial.
Verified date | July 2020 |
Source | Centre Hospitalier Universitaire, Amiens |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the
incidence is estimated at 32.1%.
Cerebrospatized patients are probably more prone to withdrawal because they require high
doses of sedation.
Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of
the therapeutic management).
Status | Completed |
Enrollment | 8 |
Est. completion date | May 16, 2018 |
Est. primary completion date | May 16, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Major Patient - Admitted in Neuroreanimation - Cerebroséé (TC-HSA-AVC) - Mono or multi failing - After a neurosedation = 3 days by hypnotic type benzodiazepine (Midazolam®) and morphinomimetic (Sufentanyl®) in IVSE - Affiliation to Social Security - Agreement of the person of confidence Exclusion Criteria: - Addiction to opiates, cocaine or cannabis - Neurological Pathology Before Hospitalization - Patient suffering from cardiac arrest - Pregnant woman - Sedation window - Patient under tutelage or curatorship or deprived of public law |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens Picardie | Amiens | Picardie |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire, Amiens |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | A variation of the Jasinski score between H0 (stop sedation) and H6. This score measures the signs of withdrawal | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04422808 -
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
|
||
Not yet recruiting |
NCT05512091 -
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use
|
||
Recruiting |
NCT05883358 -
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
|
||
Completed |
NCT03573479 -
Early Rehabilitation in Critically Ill Children - The PICU Liber8 Study
|
||
Completed |
NCT03018977 -
Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT
|
N/A | |
Completed |
NCT05336656 -
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
|
||
Terminated |
NCT03645603 -
Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)
|
Phase 2 | |
Completed |
NCT03996096 -
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.
|